- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
Patent holdings for IPC class A61K 31/64
Total number of patents in this class: 424
10-year publication summary
|
24
|
35
|
28
|
30
|
42
|
49
|
32
|
26
|
36
|
22
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Remedy Pharmaceuticals, Inc. | 57 |
52 |
| Pharnext | 79 |
12 |
| Zydus Lifesciences Limited | 140 |
11 |
| Inflazome Limited | 84 |
8 |
| Askat Inc. | 49 |
7 |
| The United States of America as represented by the Department of Veterans Affairs | 298 |
7 |
| Atxa Therapeutics Limited | 14 |
7 |
| Aratana Therapeutics, Inc. | 28 |
6 |
| Ozstar Therapeutics Pty Ltd | 6 |
6 |
| University of Maryland, Baltimore | 1071 |
6 |
| Assistance Publique - Hopitaux de Paris | 1060 |
5 |
| Biogen Chesapeake LLC | 8 |
5 |
| Boehringer Ingelheim International GmbH | 4480 |
4 |
| Ammtek | 5 |
4 |
| The University of Queensland | 651 |
4 |
| Genesis Pharma SA | 7 |
4 |
| Novartis Inflammasome Research, Inc. | 10 |
4 |
| Nodthera Limited | 45 |
4 |
| Zomagen Biosciences Ltd | 21 |
4 |
| Cxs Therapeutics | 4 |
4 |
| Other owners | 260 |